Welcome! We regret to inform you that the Injury Board National News Desk has been discontinued. Feel free to browse around and enjoy our previously published articles, or visit The Injury Blog Network for the latest in personal injury news.

Merck’s Acquisition of Schering-Plough

Posted by Jane Akre
Monday, March 09, 2009 6:12 PM EST
Category: Major Medical, Protecting Your Family
Tags: Merck, Vioxx, Schering-Plough, Big Pharma, Zocor, Singulair

Richard Clark will oversee the new Merck, merging with Schering-Plough.



IMAGE SOURCE: Portland Tribune Web site/ image of Richard Clark CEO, Merck


After shying away from acquisition, Merck has announced plans to acquire New Jersey drugmaker Schering –Plough for $41.1 billion.

The merger will still be called Merck, and for the next two years will be headed by Merck Chief Executive, Richard Clark.

The deal echos another one for two drug giants, Pfizer agreeing weeks ago to buy Wyeth for $68 billion.

Changes among pharmaceutical companies are sparked by the loss of patents on blockbuster drugs coupled with proposals to reform healthcare that may see the price of drugs drop.

Schering-Plough CEO Fred Hassan tells Reuters, “Merck came to us at the very time these changes were unfolding.”

Merck and Schering-Plough already market the cholesterol drugs, Zetia and Vytorin together.  With the merger Merck hopes to reduce its work force by 15 percent.

Merck has a long tradition of avoiding major acquisitions in its 117-year history.

Merck CEO Richard Clark, who joined the company in 1972 and worked in manufacturing and operations, had only witnessed one major transaction on his watch – the $4.85 billion settlement for thousands of Vioxx liability claims by former users who suffered heart attacks and stroke.

Clark later replaced Chief Executive Raymond Gilmartin in 2005, who lost his job after Vioxx was pulled off the market.He’s been at the helm when two patent giants, Zocor and Fosamax expired, yet earnings continued to grow.

Meanwhile Gardasil, the HPV vaccine for young girls, asthma drug Singulair and cholesterol drugs Vytorin and Zetia have seen demand fall. The new Merck hopes to expand into biotechnology.  

Clark, 63, is just two years away from mandatory retirement age. #

1 Comment

Anonymous User
Posted by JOAN PETTY
Friday, March 13, 2009 4:51 PM EST

You are right,Clark is the right man for the job. He was involved with Merck and Vioxx from day one and is now part of the Racketeering, Influnce,Corrupt, Organization RICO case filed in the United States Supreme Court. I don't think he is as innocent as he looks. He knew and was willing to leave Vioxx on the market for 5 years knowing that the toxic drug was going to kill and did kill 88,000 innocent Americans, injured 169,000. How can anyone associate themselves with a person who committed this kind of crime for profits? The case has been served to the Justice Dept.Merck & Co. Inc. and Clark thinks he is above the law.

Comments for this article are closed.

About the National News Desk

Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery.  We are committed to serving the public with honesty and integrity in these efforts.

Hurt in an accident? Contact an Injury Board member

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address


RSS Feed

Add the National News Desk to your favorite RSS reader

Add to Google Reader Add to myYahoo Add to myMSN Add to Bloglines Add to Newsgator Add to Netvibes Add to Pageflakes